SVB Leerink Downgrades Pacira Pharmaceuticals (PCRX) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $36.35 +0.11%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 8 | New: 13
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 8 | New: 13
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Outperform to Market Perform with a price target of $75.00.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $73.34 yesterday.
You May Also Be Interested In
- H.C. Wainwright Downgrades Pacira Pharmaceuticals (PCRX) to Neutral
- Piper Sandler Downgrades AST Spacemobile (ASTS) to Neutral
- Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
